AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31138321 — intervention group
Group type: COMPARATOR
Intervention: Double purse-string anastomosis
Number of subjects: 500
Study 28689688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80mg/d) combined with lithium or valproate
Number of subjects: 496
Study 28689688 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with lithium or valproate
Number of subjects: 496
Study 25061715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid message containing both statistical and narrative descriptions of HPV
Number of subjects: 174
Study 25061715 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person narrative message
Number of subjects: 174
Study 25061715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both evidence type and narrative type
Number of subjects: 174
Study 23380292 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom
Number of subjects: 24
Study 23380292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21206933 — intervention group
Group type: EXPERIMENTAL
Intervention: +MAG
Number of subjects: 116
Study 21206933 — intervention group
Group type: COMPARATOR
Intervention: -MAG
Number of subjects: 116
Study 19404957 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg VX-702 daily plus methotrexate (MTX)
Number of subjects: 430
Study 19404957 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg VX-702 twice weekly plus methotrexate (MTX)
Number of subjects: 430
Study 19404957 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg VX-702
Number of subjects: 430
Study 19404957 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg VX-702
Number of subjects: 430
Study 19404957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 19404957 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-702 groups
Number of subjects: 430
Study 19404957 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-702
Number of subjects: 430
Study 17468788 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture in conjunction with conventional rehabilitation
Number of subjects: 63
Study 17468788 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation alone
Number of subjects: 63
Study 15542517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28
Study 15542517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11677802 — intervention group
Group type: EXPERIMENTAL
Intervention: Information to patient and family doctor
Number of subjects: 100
Study 11677802 — intervention group
Group type: COMPARATOR
Intervention: No specific information about return to work (Control)
Number of subjects: 100
Study 11677802 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance subgroup
Number of subjects: 100
Study 11677802 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel patients subgroup
Number of subjects: 100
Study 9039611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic gadolinium-enhanced MR angiography (MRA)
Number of subjects: 65
Study 9039611 — intervention group
Group type: COMPARATOR
Intervention: Catheter angiography
Number of subjects: 65
Study 9039611 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 65
Study 8176573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with corticotropin (ACTH) - 150 U/m2 per day for 3 weeks, 80 U/m2 per day for 2 weeks, 80 U/m2 every other day for 3 weeks, and 50 U/m2 per day every other day for 1 week, tapered to zero over 3 weeks.
Number of subjects: 50
Study 8176573 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy with corticotropin (ACTH) - 20 to 30 U/day for 2 to 6 weeks, tapered to zero over 1 week.
Number of subjects: 50
Study 2855105 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg orally) + LVP (0.06 IU/kg i.v. over 1 h)
Number of subjects: 11
Study 2855105 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (16 mg orally) + Placebo + LVP (0.06 IU/kg i.v. over 1 h)
Number of subjects: 11
Study 2855105 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg orally) + CRH (1 micrograms/kg i.v. as bolus)
Number of subjects: 11
Study 2855105 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CRH (1 micrograms/kg i.v. as bolus)
Number of subjects: 11
Study 31967742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 44
Study 31967742 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 44
Study 30597583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 36
Study 30597583 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 36
Study 29282027 — intervention group
Group type: EXPERIMENTAL
Intervention: DePuy Synthes® VA‐LCP
Number of subjects: 20
Study 29282027 — intervention group
Group type: COMPARATOR
Intervention: Medartis® Aptus Elbow
Number of subjects: 20
Study 25158295 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 55
Study 25158295 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 55
Study 25158295 — intervention group
Group type: EXPERIMENTAL
Intervention: High electrolyte drink
Number of subjects: 55
Study 25158295 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 55
Study 23839175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%-benzoyl peroxide 2.5% gel (adapalene-BPO)
Number of subjects: 285
Study 23839175 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 285
Study 21030529 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Number of subjects: 1562
Study 21030529 — intervention group
Group type: COMPARATOR
Intervention: Mailed self-help
Number of subjects: 1562
Study 19121495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin (Ortho-Coat) with Transbond Plus self-etching primer
Number of subjects: 80
Study 19121495 — intervention group
Group type: COMPARATOR
Intervention: Transbond Plus self-etching primer without fluoride resin
Number of subjects: 80
Study 19121495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial self-etching primer (Clearfil Protect Bond) without fluoride resin
Number of subjects: 80
Study 19121495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial self-etching primer (Clearfil Protect Bond) with fluoride resin (Ortho-Coat)
Number of subjects: 80
Study 18063500 — intervention group
Group type: EXPERIMENTAL
Intervention: glyburide/metformin 2.5 mg/500 mg
Number of subjects: 100
Study 18063500 — intervention group
Group type: EXPERIMENTAL
Intervention: glyburide/metformin 5.0 mg/500 mg
Number of subjects: 100
Study 18063500 — intervention group
Group type: COMPARATOR
Intervention: glyburide 5 mg b.i.d.
Number of subjects: 100
Study 18063500 — intervention group
Group type: COMPARATOR
Intervention: metformin 500 mg b.i.d.
Number of subjects: 100
Study 15094151 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported treadmill ambulation training
Number of subjects: 2
Study 15094151 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled withdrawal of anti-spasticity medications
Number of subjects: 2
Study 11601748 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg via Aerolizer
Number of subjects: 24
Study 11601748 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg via Diskhaler
Number of subjects: 24
Study 11601748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9529028 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage‐colony stimulating factor (GM‐CSF) at a dose of 10 microg/kg per day, administered subcutaneously, on a 14‐days‐on/14‐days‐off schedule
Number of subjects: 24
Study 9529028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at a dose of 400 mg administered orally 4 times per day
Number of subjects: 24
Study 7977546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyometrial 15‐methyl prostaglandin F2 alpha, 125 micrograms
Number of subjects: 60
Study 7977546 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin, 20 U
Number of subjects: 60
Study 2690762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6 benzo-[alpha]-pyrone (coumarin, '56 BaP')
Number of subjects: 169
Study 2690762 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 169
Study 30145307 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-SAD group
Number of subjects: 162
Study 30145307 — intervention group
Group type: COMPARATOR
Intervention: MDD group
Number of subjects: 162
Study 30145307 — intervention group
Group type: COMPARATOR
Intervention: HC group
Number of subjects: 162
Study 27174580 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal insulin
Number of subjects: 40
Study 27174580 — intervention group
Group type: COMPARATOR
Intervention: No insulin (control)
Number of subjects: 40
Study 26577187 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collection with preservatives (thymol, toluene, and boric acid)
Number of subjects: 0
Study 26577187 — intervention group
Group type: COMPARATOR
Intervention: Urine collection without preservatives
Number of subjects: 0
Study 26577187 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collection protocol in NEPTUNE
Number of subjects: 0
Study 24278119 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group partner during the Joint Simon Task
Number of subjects: 0
Study 24278119 — intervention group
Group type: COMPARATOR
Intervention: Out-group partner during the Joint Simon Task
Number of subjects: 0
Study 21144709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral piroxicam 20mg
Number of subjects: 53
Study 21144709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam 20mg
Number of subjects: 53
Study 21144709 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 53
Study 18499605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane inhalation (0.5-1 vol % end-tidal concentration in oxygen 50 vol %)
Number of subjects: 10
Study 18499605 — intervention group
Group type: COMPARATOR
Intervention: Inhaling oxygen (50 vol %) alone
Number of subjects: 10
Study 16864104 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 53
Study 16864104 — intervention group
Group type: COMPARATOR
Intervention: Tube drainage (TD)
Number of subjects: 53
Study 12752022 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cognitive-behavioral group treatment
Number of subjects: 32
Study 9807980 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 24
Study 9807980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (10 mg)
Number of subjects: 24
Study 9807980 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg) + Dextroamphetamine (10 mg)
Number of subjects: 24
Study 7701460 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion for 60 minutes
Number of subjects: 8
Study 7701460 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP) infusion for 60 minutes
Number of subjects: 8
Study 7701460 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 60 minutes
Number of subjects: 8
Study 2715552 — intervention group
Group type: EXPERIMENTAL
Intervention: LY171883 (400 mg)
Number of subjects: 6
Study 2715552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 324270 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose (Celevac) - two tablets daily
Number of subjects: 30
Study 324270 — intervention group
Group type: COMPARATOR
Intervention: Placebo - two tablets daily
Number of subjects: 30
Study 324270 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose (Celevac) - two tablets daily (crossover group)
Number of subjects: 30
Study 31294134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 132
Study 31294134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 132
Study 31294134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 132
Study 28651526 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 28651526 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study 24435717 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based asthma actions delivered at the index visit
Number of subjects: 177
Study 24435717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive medication action at the time of an office visit
Number of subjects: 177
Study 24435717 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma morbidity assessment at 2 month follow-up
Number of subjects: 177
Study 22470548 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning with visual feedback
Number of subjects: 15
Study 22470548 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning without visual feedback
Number of subjects: 15
Study 22470548 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple hand movements
Number of subjects: 15
Study 22470548 — intervention group
Group type: COMPARATOR
Intervention: Control condition (untrained hand)
Number of subjects: 15
Study 19437082 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 19
Study 17518554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cautionary instructions regarding believability of participants' simulation
Number of subjects: 510
Study 17518554 — intervention group
Group type: EXPERIMENTAL
Intervention: Different financial incentive levels
Number of subjects: 510
Study 17518554 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid psychiatric diagnostic training (PTSD + MDD vs. PTSD only)
Number of subjects: 510
Study 15226632 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (10 mg twice a day)
Number of subjects: 160
Study 11268711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg for 24 weeks
Number of subjects: 90
Study 9822940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg three times daily)
Number of subjects: 43
Study 8130042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 20 ml
Number of subjects: 45
Study 8130042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 20 ml
Number of subjects: 45
Study 8130042 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl 20 ml (Control)
Number of subjects: 45
Study 8130042 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 45
Study 2808260 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (dosages: 0.3 mg/kg, 0.6 mg/kg, 1.0 mg/kg)
Number of subjects: 19
Study 2808260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 320829 — intervention group
Group type: EXPERIMENTAL
Intervention: Gangliosides
Number of subjects: 60
Study 320829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31822294 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + Feedback + Consultation
Number of subjects: 0
Study 31822294 — intervention group
Group type: COMPARATOR
Intervention: Training Only
Number of subjects: 0
Study 27666392 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing before a timed math test
Number of subjects: 122
Study 26359327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 day patch (12.5-50.0 µg/h)
Number of subjects: 476
Study 26359327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study 23370149 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n=39) received 0.1 ml of purified Vero cell rabies vaccine (PVRV) intradermally on days 0 and 21.
Number of subjects: 55
Study 23370149 — intervention group
Group type: COMPARATOR
Intervention: Group B (n=16) received 0.5 ml of PVRV intramuscularly on days 0, 7, and 21.
Number of subjects: 55
Study 21078710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 244
Study 21078710 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation-guided injection
Number of subjects: 244
Study 19268499 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopregnanolone (intravenous administration)
Number of subjects: 28
Study 19268499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous administration)
Number of subjects: 28
Study 16903602 — intervention group
Group type: EXPERIMENTAL
Intervention: Centro-square needling and triple needling
Number of subjects: 60
Study 16903602 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture therapy with motor therapy
Number of subjects: 60
Study 16516010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder retraining
Number of subjects: 708
Study 16516010 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinic therapy
Number of subjects: 708
Study 14748458 — intervention group
Group type: EXPERIMENTAL
Intervention: Using both hands
Number of subjects: 48
Study 14748458 — intervention group
Group type: EXPERIMENTAL
Intervention: Under the left arm
Number of subjects: 48
Study 14748458 — intervention group
Group type: EXPERIMENTAL
Intervention: Under the right arm
Number of subjects: 48
Study 14748458 — intervention group
Group type: COMPARATOR
Intervention: Running without the ball
Number of subjects: 48
Study 10501823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation of 200 mg p.o. per day
Number of subjects: 19
Study 10501823 — intervention group
Group type: COMPARATOR
Intervention: Dialysis treatment
Number of subjects: 19
Study 8568117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (0.5 g twice daily)
Number of subjects: 40
Study 8568117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2041034 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 38
Study 2041034 — intervention group
Group type: COMPARATOR
Intervention: prazosin
Number of subjects: 38
Study 7192117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxydiazine administered with a test meal
Number of subjects: 0
Study 7192117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxydiazine administered with a high-lipid meal
Number of subjects: 0
Study 7192117 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxydiazine administered with high-protein or high-carbohydrate meals
Number of subjects: 0
Study 31995215 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated black callers
Number of subjects: 804
Study 31995215 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Hispanic callers
Number of subjects: 804
Study 31567447 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 31567447 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatments
Number of subjects: 0
Study 28887058 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program performed 3 times a week during HD sessions
Number of subjects: 44
Study 28887058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 44
Study 25869993 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1601
Study 25869993 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 1601
Study 24257657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Group 1)
Number of subjects: 172
Study 24257657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissucol (fibrinogen and thrombin) (Group 2)
Number of subjects: 172
Study 24257657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (Group 3)
Number of subjects: 172
Study 24257657 — intervention group
Group type: COMPARATOR
Intervention: Routine hemostasis (Control Group 4)
Number of subjects: 172
Study 20931346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (CT)
Number of subjects: 40
Study 20931346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19167797 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15% energy from protein)
Number of subjects: 378
Study 19167797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV) diet (15% energy from protein)
Number of subjects: 378
Study 19167797 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (18% energy from protein)
Number of subjects: 378
Study 19167797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV) diet
Number of subjects: 378
Study 17896083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramsay scale
Number of subjects: 237
Study 14752668 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT (+) patients
Number of subjects: 29
Study 14752668 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT (−) patients
Number of subjects: 29
Study 14752668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HRCT (+) and HRCT (−) patients
Number of subjects: 29
Study 11348938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol dry powder, 12 microg bid, in addition to ipratropium bromide, 40 microg qid for 3 weeks
Number of subjects: 172
Study 11348938 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol, 200 microg qid, in addition to ipratropium, 40 microg qid for 3 weeks
Number of subjects: 172
Study 9212293 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 400 mg
Number of subjects: 18
Study 9212293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8484645 — intervention group
Group type: EXPERIMENTAL
Intervention: Raja pleural biopsy needle
Number of subjects: 31
Study 8484645 — intervention group
Group type: COMPARATOR
Intervention: Abrams pleural biopsy needle
Number of subjects: 31
Study 3326116 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 99
Study 3326116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 99
Study 3326116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 30610875 — intervention group
Group type: EXPERIMENTAL
Intervention: online HD‐atDCS
Number of subjects: 9